西藏藥業(600211.SH):暫停rhIL-1Ra滴眼液的臨牀試驗及後續研發事項
格隆匯3月11日丨西藏藥業(600211.SH)公佈,公司與全資子公司成都諾迪康生物製藥有限公司研發的重組人白細胞介素-1受體拮抗劑(rhIL-1Ra)滴眼液項目已完成IIa期臨牀實驗研究,試驗結果不及預期。經綜合評估,公司決定暫停該新藥的臨牀試驗及後續研發。
重組人白細胞介素-1受體拮抗劑(rhIL-1Ra)滴眼液,為公司自主研發的產品,擬用於輕、中度角膜非感染性炎症的治療,已完成IIa期臨牀實驗研究。根據IIa期臨牀試驗結果顯示,rhIL-1Ra滴眼液安全性良好,但有效性需進一步探索。公司經審慎考量,基於對該滴眼液繼續開發的風險性和未來臨牀價值的評估,以及後續開發投入和藥物療效的不確定性,決定暫停該藥物的進一步研發。
截至公吿日,公司及全資子公司針對該新藥全部研發投入為人民幣2174.15萬元。按照相關會計準則和公司會計政策,該新藥的研發投入已全部計入2021年度期間損益。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.